Cas9 Stable Cell Line - EA.hy926

The EA.hy926 cell line is a hybrid cell line derived from the fusion of human umbilical vein endothelial cells (HUVECs) and the human lung cancer cell line A549. This fusion produces a stable cell line that retains key endothelial cell characteristics, including the expression of factor VIII-related antigens and the ability to form capillary-like structures. The Cas9-stable cell line EA.hy926 is a genetically engineered derivative cell line in which the Cas9 endonuclease is stably integrated into the genome. This modification allows CRISPR-Cas9 function to continue without repeated transfection, enabling efficient and stable genome editing. This cell line retains endothelial cell characteristics such as angiotensin-converting enzyme (ACE) activity and von Willebrand factor (vWF) production, making it a valuable model for vascular biology research.

This engineered cell line has broad application prospects in vascular and cancer research. Scientists use this system to study the mechanisms of endothelial dysfunction in diseases such as atherosclerosis and diabetes by knocking out genes involved in inflammation, oxidative stress, or angiogenesis pathways. In cancer research, this system helps construct models of tumor-endothelial cell interactions by targeting and editing oncogenes or tumor suppressor genes. The stable Cas9 system also simplifies high-throughput screening of vascular-targeted therapies, enabling rapid evaluation of compounds affecting endothelial cell proliferation or permeability. Furthermore, researchers have used this system to study endothelial-mesenchymal transition (EndMT) by editing components of the TGF-β signaling pathway. This system''s dual nature—combining the characteristics of both endothelial cells and cancer cells—makes it uniquely suited for studying the metastatic mechanisms of cancer cell-vascular endothelial cell interactions.